ReviewWorld journal of hepatology2020
Metabolic associated fatty liver disease: Addressing a new era in liver transplantation.
Review in World journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Efficacy and safety of lower-carbohydrate dietary patterns for metabolic associated fatty liver disease: evidence from randomized controlled trials with grade analysis.Nutrition & metabolism · 2026Article
- Cirrhotic cardiomyopathy: pathophysiology, assessment, and implications for liver transplantation.Therapeutic advances in gastroenterology · 2026Review
- SIRT5 affects lipid accumulation in cells of a metabolic-associated fatty liver disease model by regulating the succinylation status of HSPD1.BMC immunology · 2025Article
- Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease.Biomolecules · 2025Review
- Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and obese MASLD.JCI insight · 2025Article
- Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.Journal of cellular and molecular medicine · 2024Article
- The correlation between liver fibrosis and the 10-year estimated risk of cardiovascular disease in adults with metabolic-associated fatty liver disease: A cross-sectional study in Vietnam.Health science reports · 2024Article
- From liver to hormones: The endocrine consequences of cirrhosis.World journal of gastroenterology · 2024Review
- Predicting major adverse cardiovascular events after orthotopic liver transplantation using a supervised machine learning model: A cohort study.World journal of hepatology · 2024Article
- Technical optimization of spatially resolved single-cell transcriptomic datasets to study clinical liver disease.Scientific reports · 2024Article
- Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond.Biomedicines · 2024Review
- Intestinal Inflammation and Regeneration-Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- Co-Morbid Hypothyroidism and Liver Dysfunction: A Review.Clinical medicine insights. Endocrinology and diabetes · 2024Review
- Global liver transplantation: emerging trends and ethical challenges.Langenbeck's archives of surgery · 2023Review
- Article
- Skeptical Look at the Clinical Implication of Metabolic Syndrome in Childhood Obesity.Children (Basel, Switzerland) · 2023Review
- A Low Daily Intake of Simple Sugars in the Diet Is Associated with Improved Liver Function in Cirrhotic Liver Transplant Candidates.Nutrients · 2023Article
- Review
- Improving the prognosis before and after liver transplantation: Is muscle a game changer?World journal of gastroenterology · 2022Review
- Liver Fetuin-A at Initiation of Insulin Resistance.Metabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic associated fatty liver disease (MAFLD), previously termed non-alcoholic fatty liver disease, is the leading global cause of liver disease and is fast becoming the most common indication for liver transplantation. The recent change in nomenclature to MAFLD refocuses the conceptualisation of this disease entity to its metabolic underpinnings and may help to spur a paradigm shift in the approach to its management, including in the setting of liver transplantation. Patients with MAFLD present significant challenges in the pre-, peri- and post-transplant settings, largely due to the presence of medical comorbidities that include obesity, metabolic syndrome and cardiovascular risk factors. As the community prevalence of MAFLD increases concurrently with the obesity epidemic, donor liver steatosis is also a current and future concern. This review outlines current epidemiology, nomenclature, management issues and outcomes of liver transplantation in patients with MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.